Michael A.  Metzger net worth and biography

Michael Metzger Biography and Net Worth

Michael A. Metzger has served as our President and Chief Operating Officer since May 2015 and as a member of our board of directors since July 2019. Prior to joining us, Mr. Metzger was President and COO from December 2013 to October 2014 and President and Chief Executive Officer and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded biotechnology company that merged with Tobira Therapeutics, Inc., from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a privately held biopharmaceutical company developing novel immunoconjugate therapies for cancer, from March 2011 to November 2013, and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Mr. Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc. and was a Managing Director at MESA Partners, Inc., a venture capital firm. Mr. Metzger currently serves on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company, as well as the boards of other private and not-for-profit companies. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.

What is Michael A. Metzger's net worth?

The estimated net worth of Michael A. Metzger is at least $230,979.72 as of February 6th, 2023. Mr. Metzger owns 17,659 shares of Syndax Pharmaceuticals stock worth more than $230,980 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Metzger may own. Additionally, Mr. Metzger receives a salary of $1,100,000.00 as COO at Syndax Pharmaceuticals. Learn More about Michael A. Metzger's net worth.

How old is Michael A. Metzger?

Mr. Metzger is currently 53 years old. There are 5 older executives and no younger executives at Syndax Pharmaceuticals. Learn More on Michael A. Metzger's age.

What is Michael A. Metzger's salary?

As the COO of Syndax Pharmaceuticals, Inc., Mr. Metzger earns $1,100,000.00 per year. Learn More on Michael A. Metzger's salary.

How do I contact Michael A. Metzger?

The corporate mailing address for Mr. Metzger and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Michael A. Metzger's contact information.

Has Michael A. Metzger been buying or selling shares of Syndax Pharmaceuticals?

Michael A. Metzger has not been actively trading shares of Syndax Pharmaceuticals during the past quarter. Most recently, Michael A. Metzger sold 5,959 shares of the business's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $27.64, for a transaction totalling $164,706.76. Following the completion of the sale, the chief executive officer now directly owns 17,659 shares of the company's stock, valued at $488,094.76. Learn More on Michael A. Metzger's trading history.

Who are Syndax Pharmaceuticals' active insiders?

Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Pierre Legault (Director), Michael Metzger (COO), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Syndax Pharmaceuticals?

In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. The most recent insider tranaction occured on June, 14th when CFO Keith A Goldan bought 1,250 shares worth more than $25,037.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.

Information on this page was last updated on 6/14/2024.

Michael A. Metzger Insider Trading History at Syndax Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2023Sell5,959$27.64$164,706.7617,659View SEC Filing Icon  
10/6/2022Sell16,231$25.29$410,481.9917,659View SEC Filing Icon  
10/4/2022Sell1,280$25.02$32,025.6017,659View SEC Filing Icon  
9/30/2022Sell29,606$25.02$740,742.1217,659View SEC Filing Icon  
7/25/2022Sell31,602$21.06$665,538.1217,659View SEC Filing Icon  
7/7/2022Sell100$21.00$2,100.0017,659View SEC Filing Icon  
12/20/2021Sell61,000$20.29$1,237,690.00View SEC Filing Icon  
12/17/2021Sell1,676$19.02$31,877.52View SEC Filing Icon  
12/13/2021Sell36,609$19.05$697,401.45View SEC Filing Icon  
10/25/2021Sell44,704$19.13$855,187.52View SEC Filing Icon  
9/27/2021Sell24,437$19.51$476,765.87View SEC Filing Icon  
9/21/2021Sell4,808$19.16$92,121.28View SEC Filing Icon  
12/1/2020Sell15,000$22.97$344,550.0032,659View SEC Filing Icon  
11/4/2020Sell100,000$20.31$2,031,000.00117,659View SEC Filing Icon  
See Full Table

Michael A. Metzger Buying and Selling Activity at Syndax Pharmaceuticals

This chart shows Michael A Metzger's buying and selling at Syndax Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals logo
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $13.08
Low: $12.75
High: $13.15

50 Day Range

MA: $17.30
Low: $12.85
High: $21.81

2 Week Range

Now: $13.08
Low: $12.75
High: $25.34

Volume

4,993,342 shs

Average Volume

1,251,799 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86